Stock listing
NASDAQ:BMEA Biomea Fusion, Inc. Stock
Home listing (NASDAQ) of Biomea Fusion, Inc.
Follow Biomea Fusion, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BMEA
$0.574 USD +0.044 (+8.4%)
Close on Nov 20, 2026
- Day range
- $0.545 – $0.600 USDNov 20, 2026
- Volume
- 1.12M sharesNov 20, 2026
- Market cap
- $41.75M USDAt the close on Nov 20, 2026 · price × 72.68M shares outstanding
- 52-week range
- $0.450 – $2.237 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.80M USDMedian day 1.48M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BMEA · Home | $0.574 USD | +0.044 (+8.4%) | 1,123,083 | $0.563 | $0.600 | $0.545 | $0.530 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BMEA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.574 | +0.044 | +8.4% | $0.563 | $0.600 | $0.545 | 1,123,083 | |
| $0.530 | +0.042 | +8.6% | $0.495 | $0.530 | $0.450 | 1,043,230 | |
| $0.488 | -0.032 | -6.2% | $0.546 | $0.555 | $0.463 | 1,200,006 | |
| $0.520 | -0.062 | -10.7% | $0.583 | $0.583 | $0.520 | 512,390 | |
| $0.582 | +0.020 | +3.5% | $0.575 | $0.600 | $0.540 | 562,779 | |
| $0.563 | -0.048 | -7.9% | $0.610 | $0.625 | $0.563 | 839,006 | |
| $0.611 | +0.064 | +11.7% | $0.569 | $0.620 | $0.541 | 694,311 | |
| $0.547 | -0.048 | -8.1% | $0.606 | $0.615 | $0.546 | 788,539 | |
| $0.595 | +0.028 | +5.0% | $0.576 | $0.619 | $0.548 | 737,128 | |
| $0.567 | -0.021 | -3.5% | $0.578 | $0.600 | $0.540 | 1,778,841 | |
| $0.587 | -0.024 | -4.0% | $0.613 | $0.628 | $0.540 | 1,437,114 | |
| $0.612 | -0.012 | -1.9% | $0.622 | $0.675 | $0.608 | 912,982 | |
| $0.624 | -0.036 | -5.5% | $0.648 | $0.692 | $0.624 | 948,512 | |
| $0.660 | +0.020 | +3.2% | $0.636 | $0.660 | $0.620 | 792,803 | |
| $0.640 | +0.017 | +2.7% | $0.630 | $0.649 | $0.590 | 1,099,866 | |
| $0.623 | -0.025 | -3.8% | $0.633 | $0.660 | $0.620 | 677,152 | |
| $0.648 | +0.005 | +0.8% | $0.650 | $0.660 | $0.622 | 751,923 | |
| $0.642 | +0.007 | +1.1% | $0.634 | $0.663 | $0.603 | 1,312,031 | |
| $0.636 | +0.036 | +5.9% | $0.598 | $0.636 | $0.552 | 1,528,167 | |
| $0.600 | +0.015 | +2.6% | $0.590 | $0.633 | $0.585 | 958,013 | |
| $0.585 | -0.105 | -15.2% | $0.661 | $0.700 | $0.581 | 1,957,330 | |
| $0.690 | -0.045 | -6.2% | $0.740 | $0.750 | $0.684 | 3,040,670 | |
| $0.736 | -0.100 | -12.0% | $0.840 | $0.913 | $0.736 | 3,551,160 | |
| $0.836 | -0.033 | -3.8% | $0.906 | $0.906 | $0.830 | 1,565,580 | |
| $0.869 | +0.032 | +3.9% | $0.839 | $0.970 | $0.800 | 3,786,094 | |
| $0.836 | +0.002 | +0.3% | $0.820 | $0.890 | $0.802 | 3,135,200 | |
| $0.834 | -0.426 | -33.8% | $0.999 | $0.999 | $0.801 | 11,712,700 | |
| $1.260 | -0.100 | -7.4% | $1.435 | $1.437 | $1.230 | 8,316,156 | |
| $1.360 | -0.060 | -4.2% | $1.440 | $1.460 | $1.360 | 5,368,917 | |
| $1.420 | +0.050 | +3.6% | $1.380 | $1.450 | $1.380 | 1,170,623 | |
| $1.370 | +0.050 | +3.8% | $1.320 | $1.380 | $1.300 | 1,706,889 | |
| $1.320 | +0.070 | +5.6% | $1.270 | $1.340 | $1.250 | 836,126 | |
| $1.250 | -0.050 | -3.8% | $1.280 | $1.310 | $1.240 | 797,006 | |
| $1.300 | +0.030 | +2.4% | $1.270 | $1.310 | $1.220 | 1,044,351 | |
| $1.270 | -0.030 | -2.3% | $1.300 | $1.305 | $1.260 | 844,359 | |
| $1.300 | -0.030 | -2.3% | $1.320 | $1.360 | $1.300 | 1,069,849 | |
| $1.330 | +0.070 | +5.6% | $1.290 | $1.370 | $1.260 | 1,453,276 | |
| $1.260 | -0.030 | -2.3% | $1.280 | $1.300 | $1.250 | 1,556,142 | |
| $1.290 | -0.030 | -2.3% | $1.320 | $1.365 | $1.270 | 1,456,718 | |
| $1.320 | -0.170 | -11.4% | $1.490 | $1.490 | $1.303 | 3,083,456 | |
| $1.490 | +0.050 | +3.5% | $1.460 | $1.500 | $1.390 | 2,185,403 | |
| $1.440 | -0.260 | -15.3% | $1.700 | $1.720 | $1.350 | 9,301,263 | |
| $1.700 | -0.010 | -0.6% | $1.710 | $1.780 | $1.660 | 2,337,434 | |
| $1.710 | -0.120 | -6.6% | $1.840 | $1.850 | $1.675 | 1,785,868 | |
| $1.830 | +0.040 | +2.2% | $1.790 | $1.930 | $1.770 | 1,630,910 | |
| $1.790 | +0.050 | +2.9% | $1.780 | $1.835 | $1.720 | 1,374,295 | |
| $1.740 | -0.060 | -3.3% | $1.800 | $1.835 | $1.705 | 1,596,476 | |
| $1.800 | +0.020 | +1.1% | $1.790 | $1.815 | $1.660 | 1,344,127 | |
| $1.780 | +0.040 | +2.3% | $1.715 | $1.790 | $1.660 | 1,552,492 | |
| $1.740 | +0.040 | +2.4% | $1.750 | $1.780 | $1.700 | 1,481,264 | |
| $1.700 | -0.145 | -7.9% | $1.830 | $1.840 | $1.680 | 2,501,258 | |
| $1.845 | -0.085 | -4.4% | $1.940 | $1.959 | $1.815 | 2,505,189 | |
| $1.930 | -0.100 | -4.9% | $2.000 | $2.070 | $1.890 | 1,853,308 | |
| $2.030 | +0.120 | +6.3% | $1.900 | $2.050 | $1.885 | 3,291,010 | |
| $1.910 | -0.025 | -1.3% | $1.930 | $1.980 | $1.840 | 1,759,412 | |
| $1.935 | +0.135 | +7.5% | $1.805 | $1.940 | $1.710 | 2,136,579 | |
| $1.800 | +0.120 | +7.1% | $1.680 | $1.870 | $1.671 | 2,266,537 | |
| $1.680 | -0.050 | -2.9% | $1.720 | $1.800 | $1.680 | 1,018,960 | |
| $1.730 | +0.050 | +3.0% | $1.690 | $1.745 | $1.650 | 1,168,229 | |
| $1.680 | -0.030 | -1.8% | $1.740 | $1.850 | $1.665 | 1,838,255 | |
| $1.710 | -0.020 | -1.2% | $1.755 | $1.830 | $1.650 | 3,218,753 | |
| $1.730 | +0.140 | +8.8% | $1.630 | $1.810 | $1.580 | 4,457,477 | |
| $1.590 | +0.220 | +16.1% | $1.510 | $1.770 | $1.495 | 11,503,100 | |
| $1.370 | +0.010 | +0.7% | $1.370 | $1.380 | $1.320 | 572,700 | |
| $1.360 | -0.030 | -2.2% | $1.370 | $1.380 | $1.320 | 532,472 |
- Ticker
- NASDAQ:BMEA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Biomea Fusion to Participate in Upcoming Investor Conferences
Latest deck · Oct 14, 2026
Technical Presentation (October 2026)
Technical · 29 slides
Latest news
Biomea Fusion to Participate in Upcoming Investor Conferences
Nov 12, 2026
Closed $0.582 (+3.5%) on Nov 13, 2026
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
Nov 10, 2026
Closed $0.611 (+11.7%) on Nov 11, 2026
Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026
Nov 10, 2026
Closed $0.547 (-8.1%) on Nov 10, 2026
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
Oct 13, 2026
Closed $0.834 (-33.8%) on Oct 14, 2026
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Oct 12, 2026
Closed $1.26 (-7.4%) on Oct 13, 2026
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Sep 23, 2026
Closed $1.44 (-15.3%) on Sep 23, 2026
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Aug 24, 2026
Closed $1.59 (+16.1%) on Aug 24, 2026
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Aug 13, 2026
Closed $1.28 (0.0%) on Aug 13, 2026
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Aug 5, 2026
Closed $1.25 (-0.8%) on Aug 6, 2026
Biomea Fusion, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 129 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 20 decks · latest Oct 14, 2026
Where Biomea Fusion, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BMEA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BMEA | BOATS | United States | USD |
Valuation
Price/book 5.5× against a median of 3.0×: 7th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $15.85M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.14
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Biomea Fusion, Inc. · NASDAQ:BMEA | US$41.75M | US$15.85M | n/a | n/a | n/a | 5.5× | n/a | 0.1× | 1.14 |
| Spero Therapeutics, Inc. · NASDAQ:SPRO | US$43.23M | −US$63.10M | n/a | −1.5× | n/a | 55.4× | −71.0% | 2.0× | 1.68 |
| Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX | US$43.15M | −US$1.28M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | n/a |
| Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP | US$42.45M | −US$68.98M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 1.85 |
| Arecor Therapeutics PLC · LSE:AREC | US$42.37M | US$38.32M | 48.8× | 17.1× | n/a | 8.8× | 38.7% | 0.0× | n/a |
| OS Therapies Incorporated · AMEX:OSTX | US$42.00M | US$41.57M | n/a | n/a | n/a | n/a | n/a | n/a | 1.70 |
| Advagene Biopharma Co., Ltd. · TPEX:6709 | US$41.89M | US$32.03M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| Prescient Therapeutics Limited · ASX:PTX | US$41.64M | US$35.80M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Mereo BioPharma Group plc · NASDAQ:MREO | US$41.52M | US$16.00M | n/a | 20.0× | n/a | 1.8× | n/a | 0.0× | 1.34 |
| Elicio Therapeutics, Inc. · NASDAQ:ELTX | US$41.05M | US$19.78M | n/a | n/a | n/a | 2.2× | n/a | 0.5× | 1.81 |
| MiNK Therapeutics, Inc. · NASDAQ:INKT | US$40.93M | US$33.46M | n/a | 167× | n/a | n/a | n/a | n/a | 0.81 |
| Median of the others | US$41.94M | US$25.90M | 48.8× | 18.6× | 3.0× | −16.1% | 0.0× | 1.69 |
Forecasts
4 strong buy · 2 buy · 1 sell · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.62 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Michael J.M. Hitchcock | Interim Chief Executive Officer and Director |
| Rainer Erdtmann | President, Chief Operating Officer and Director |
| Ramses Erdtmann | Chief Operating Officer and President |
| Meichiel Jennifer Weiss | Sr. Director of Investor Relations and Corporate Development |
| Juan Pablo Frias | Chief Medical Officer and Head of Diabetes |
Board
| Director | Role |
|---|---|
| Bihua Chen | Director |
| Elizabeth Faust | Director |
| Eric Aguiar | Lead Independent Director |
| Michael J.M. Hitchcock | Interim Chief Executive Officer and Director |
| Rainer Erdtmann | President, Chief Operating Officer and Director |
| Sumita Ray | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +11.7% |
| Q2 2026 | Aug 5, 2026 · After close | −0.8% |
| Q1 2026 | May 11, 2026 · After close | +0.6% |
| Q4 2025 | Mar 25, 2026 | +21.2% |
| Q3 2025 | Nov 4, 2025 · After close | +6.3% |
| Q2 2025 | Aug 5, 2025 · After close | +0.6% |
| Q1 2025 | May 5, 2025 · After close | −16.5% |
| Q4 2024 | Mar 31, 2025 | −13.5% |
| Q3 2024 | Oct 29, 2024 · After close | −14.3% |
| Q2 2024 | Jul 31, 2024 · After close | +3.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | +3.5% |
| Q4 2023 | Jan 9, 2024 · After close | +2.9% |
| Q3 2023 | Oct 30, 2023 · After close | −7.6% |
| Q2 2023 | Jul 31, 2023 · After close | −6.7% |
| Q1 2023 | May 2, 2023 · After close | +5.8% |
| Q4 2022 | Mar 28, 2023 · After close | +5.3% |
| Q3 2022 | Nov 7, 2022 · After close | −6.1% |
| Q2 2022 | Aug 1, 2022 · After close | +4.3% |
| Q1 2022 | May 16, 2022 · Before open | +0.5% |
| Q4 2021 | Feb 28, 2022 · After close | −7.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (October 2026) | Technical | 29 slides | Oct 14, 2026 |
| Corporate Update (April 2026) | Corporate update | 27 slides | Apr 28, 2026 |
| Investor Presentation (February 2026) | Investor deck | 37 slides | Feb 25, 2026 |
| 2026 J.P. Morgan Healthcare Conference | Conference | 27 slides | Jan 14, 2026 |
| Investor Presentation (January 2026) | Investor deck | 51 slides | Jan 14, 2026 |
| Corporate Update (June 2025) | Corporate update | 56 slides | Jun 17, 2025 |
| American Diabetes Association (ADA) 2025 Scientific Sessions | Conference | 20 slides | June 2025 |
| 43rd Annual J.P. Morgan Healthcare Conference (January 2025) | Conference | 39 slides | Jan 15, 2025 |
| Technical Presentation (December 2024) | Technical | 25 slides | Dec 20, 2024 |
| Technical Presentation (October 2024) | Technical | 26 slides | Oct 31, 2024 |
All 20 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| JP Morgan Healthcare Conference 2024 | Conference | 32 slides | Jan 10, 2024 |
| Technical Presentation (December 2023) | Technical | 21 slides | Dec 8, 2023 |
| WCIRDC Breakfast Symposium 2023 | Conference | 51 slides | Dec 7, 2023 |
| Technical Presentation (March 2023) | Technical | 18 slides | Mar 28, 2023 |
| JP Morgan Healthcare Conference 2023 | Conference | 53 slides | Jan 12, 2023 |
| EASD Annual Meeting 2022 | Conference | 23 slides | Sep 22, 2022 |
| EASD Annual Meeting 2022 | Conference | 10 slides | Sep 22, 2022 |
| Investor Presentation (January 2022) | Investor deck | 40 slides | Jan 12, 2022 |
| Investor Presentation (November 2021) | Investor deck | 34 slides | Nov 15, 2021 |
| Investor Presentation (July 2021) | Investor deck | 25 slides | Jul 19, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of securities Cancelled: public offering | Sep 23, 2026 |
| Public offering of common stock and accompanying warrants (or pre-funded warrants in lieu thereof) Update: about US$25M · US$2.05 a share · 1 warrant at US$2.5 for 36 months · Jefferies +1 Dealers: Jefferies (lead), H.C. Wainwright & Co. (co-lead) | Oct 7, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Apr 15, 2021.
- Price
- US$17.00 a share
- Shares offered
- 9,000,000 shares of common stock
- Offering size
- US$153 million
- Underwriters' option
- Up to 1,350,000 more shares
- Underwriters
- J.P. Morgan, Jefferies, Piper Sandler · In the order on the cover
- Shares delivered
- On or about Apr 20, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 12, 2021 |
| Filed publicly | Mar 26, 2021 |
| Amended twice | Newest Apr 15, 2021 |
| Shares registered with an exchange | Apr 14, 2021 |
| Declared effective by the SEC | Apr 15, 2021 |
| Final prospectus, with the price | Apr 19, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 19, 2021 |
| EFFECT · Notice that a registration is effective | Apr 15, 2021 |
| S-1MEF · Registration of more shares for the same offering | Apr 15, 2021 |
| CERT · Exchange's certificate of listing | Apr 15, 2021 |
| S-1/A · Registration statement, amended | Apr 15, 2021 |
| CORRESP · Letter to the SEC | Apr 15, 2021 |
| UPLOAD · Letter from the SEC | Apr 15, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 14, 2021 |
| CORRESP · Letter to the SEC | Apr 13, 2021 |
| CORRESP · Letter to the SEC | Apr 13, 2021 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Apr 12, 2021 |
| S-1/A · Registration statement, amended | Apr 12, 2021 |
| UPLOAD · Letter from the SEC | Apr 2, 2021 |
| CORRESP · Letter to the SEC | Mar 26, 2021 |
| S-1 · Registration statement | Mar 26, 2021 |
| UPLOAD · Letter from the SEC | Mar 12, 2021 |
| DRS · Draft registration statement | Feb 12, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 19, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.41M | 1.75M | 4.20M | 1.26M | 953.0K | 132.0K | |
| Gross profit | -1.41M | -1.75M | -4.20M | -1.26M | -953.0K | -132.0K | |
| Research and development | 62.0M | 118.1M | 102.5M | 62.7M | 28.0M | 3.67M | 1.09M |
| Selling, general and administrative | 19.3M | 26.0M | 23.6M | 20.9M | 13.7M | 1.66M | 103.0K |
| Operating income | -83.5M | -144.1M | -126.1M | -83.6M | -41.7M | -5.33M | -1.20M |
| Depreciation and amortization | 1.41M | 1.75M | 1.51M | 691.0K | 249.0K | 8.00K | 0 |
| EBITDA | -82.1M | -142.3M | -124.6M | -82.9M | -41.4M | -5.32M | -1.20M |
| Interest expense | 1.81M | 100.0K | 0 | 0 | |||
| Income before tax | -61.8M | -138.4M | -117.3M | -81.8M | -41.6M | -5.32M | -1.20M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 3.00K |
| Net income | -61.8M | -138.4M | -117.3M | -81.8M | -41.6M | -5.32M | -1.20M |
| Earnings per share, basic | -1.18 | -3.83 | -3.44 | -2.80 | -1.74 | -0.51 | -0.20 |
| Earnings per share, diluted | -1.18 | -3.83 | -3.44 | -2.80 | -1.74 | -0.51 | -0.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 55.8M | 58.3M | 176.9M | 111.9M | 145.7M | 61.7M | 239.0K |
| Short-term investments | 0 | 1.15M | 27.8M | 0 | |||
| Receivables | 16.0K | ||||||
| Current assets | 58.0M | 68.3M | 179.2M | 117.8M | 176.6M | 62.2M | 265.0K |
| Property, plant and equipment | 153.0K | 3.77M | 5.16M | 5.84M | 2.96M | 81.0K | |
| Total assets | 58.6M | 79.9M | 199.9M | 129.3M | 185.7M | 62.5M | 265.0K |
| Accounts payable | 3.23M | 12.9M | 6.85M | 6.83M | 1.33M | 727.0K | 271.0K |
| Current liabilities | 11.1M | 21.7M | 22.9M | 19.1M | 4.64M | 1.62M | 286.0K |
| Total debt | 1.59M | 8.77M | 10.3M | 2.29M | 2.85M | 259.0K | |
| Total liabilities | 29.0M | 28.4M | 30.7M | 20.8M | 6.92M | 1.62M | 286.0K |
| Shareholders' equity | 29.6M | 51.6M | 169.2M | 108.5M | 178.8M | 5.17M | -21.0K |
| Shares outstanding | 72.3M | 36.3M | 35.9M | 29.6M | 29.1M | 12.0M | 29.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -70.4M | -119.9M | -96.6M | -62.4M | -35.4M | -4.46M | -1.28M |
| Capital spending | 0 | -362.0K | -3.37M | -1.03M | -3.17M | -51.0K | -51.0K |
| Free cash flow | -70.4M | -120.3M | -100.0M | -63.4M | -38.6M | -4.51M | -1.28M |
| Cash from investing | -362.0K | -2.22M | 27.3M | -33.4M | -51.0K | -51.0K | |
| Cash from financing | 67.9M | 1.67M | 163.8M | 1.24M | 153.2M | 66.0M | 1.44M |
| Share buybacks | 1.24M | 153.2M | |||||
| Change in cash | -2.47M | -118.6M | 65.0M | -33.8M | 84.4M | 61.5M | 161.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| 424B5 · Prospectus | Sep 22, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 22, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| 8-K · Current report | Apr 28, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 27, 2026 | Annual report | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 24, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2026 | Results | SEC |
| 8-K · Current report | Feb 25, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| 5 · Annual statement of ownership | Feb 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jan 6, 2026 | Offer document | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 24, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 7, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 7, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Oct 6, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 6, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 18, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 12, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 11, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | Aug 5, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 24, 2025 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 25, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 20, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 18, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 18, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jun 17, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 27, 2025 | Management or board change | SEC |
| 8-K · Current report | Feb 28, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 15, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jan 6, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 2, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 31, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Oct 29, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 27, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Jul 31, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2024 | Results | SEC |
| UPLOAD · Letter from the SEC | Jul 18, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Jun 21, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jun 12, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 7, 2024 | Current report | SEC |
| 8-K · Current report | May 2, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 2, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Apr 10, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Apr 1, 2024 | Current report | SEC |
| 8-K · Current report | Apr 1, 2024 | Results | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 7, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 8, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 10, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jan 5, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Oct 30, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2023 | Results | SEC |
| 4 · Change in ownership | Sep 1, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 1, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 31, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2023 | Results | SEC |
| 8-K · Current report | Jul 25, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 19, 2023 | Other filings | SEC |
| 4 · Change in ownership | May 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 10, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | May 10, 2023 | Big-stake notice | SEC |
| 8-K · Current report | May 2, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 2, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 2, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 27, 2023 | Other filings | SEC |
| 4 · Change in ownership | Apr 26, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 20, 2023 | Other filings | SEC |
| 4/A · Change in ownership, amended | Apr 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 3, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 3, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Mar 30, 2023 | Offer document | SEC |
| 424B5 · Prospectus | Mar 29, 2023 | Offer document | SEC |
| 8-K · Current report | Mar 28, 2023 | Current report | SEC |
| 10-K · Annual report | Mar 28, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2023 | Results | SEC |
| SC 13G · Big-stake notice | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| 5 · Annual statement of ownership | Feb 10, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Feb 10, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2023 | Current report | SEC |
| 4 · Change in ownership | Jan 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 4, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2022 | Current report | SEC |
| 8-K · Current report | Dec 13, 2022 | Current report | SEC |
| 4 · Change in ownership | Dec 2, 2022 | Insider trade | SEC |
| 8-K · Current report | Nov 25, 2022 | Material contract | SEC |
| 424B5 · Prospectus | Nov 25, 2022 | Offer document | SEC |
| 4 · Change in ownership | Nov 16, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2022 | Results | SEC |
| 8-K · Current report | Nov 1, 2022 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 25, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 20, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 19, 2022 | Other filings | SEC |
| 8-K · Current report | Oct 18, 2022 | Current report | SEC |
| S-3 · Registration statement | Oct 14, 2022 | Offer document | SEC |
| 8-K · Current report | Sep 22, 2022 | Current report | SEC |
| 8-K · Current report | Sep 21, 2022 | Current report | SEC |
| 8-K · Current report | Sep 9, 2022 | Material contract | SEC |
| 8-K · Current report | Aug 29, 2022 | Current report | SEC |
| 4 · Change in ownership | Aug 19, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 1, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2022 | Results | SEC |
| 4 · Change in ownership | Jul 25, 2022 | Insider trade | SEC |
This page holds 200 of 292 filings. Open Filings
Cap table
Built by 6ix from Biomea Fusion, Inc.’s releases · as of Oct 29, 2026
- Common shares
- 72,678,080
- Fully diluted
- 72,678,080
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 72,678,080 | Oct 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 29, 2026 | 72,678,080 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bihua Chen Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); Helix Acquisition Corp. III (Chairperson and CEO, Director · Since at least Jan 22, 2026); BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025) | Director · Since at least Jun 11, 2025 |
| Eric Aguiar Other companies: BridgeBio Pharma, Inc. (Director · Since at least Jun 21, 2024) | Director · Since at least Jun 12, 2024 |
| Franco Valle Other companies: Eidos Therapeutics Inc (Senior Vice President, Finance · Oct 7, 2020 – Jan 26, 2021 · Past) | Chief Financial Officer · Jul 26, 2021 – Nov 30, 2024 · Past |
| Elizabeth Faust | Director · Since at least Jun 22, 2022 |
| Juan Pablo Frias | Chief Medical Officer and Head of Diabetes · Since at least Aug 31, 2023 |
| Julianne Averill | Director · Jul 24, 2025 – Nov 5, 2026 · Past |
| Meichiel Jennifer Weiss | Sr. Director of Investor Relations and Corporate Development · Since at least May 11, 2026 |
| Michael J.M. Hitchcock | Interim Chief Executive Officer and Director · Since at least Mar 25, 2025 |
| Rainer Erdtmann | See Remarks, Director · Since at least Dec 29, 2023 |
| Ramses Erdtmann | Chief Operating Officer and President · Since at least Dec 17, 2024 |
All 12 people
| Person | Seat |
|---|---|
| Sunny Ryan | EVP of Finance · Apr 15, 2021 – Apr 15, 2021 · Past |
| Thomas Butler | Chief Executive Officer, Director · Apr 15, 2021 – Mar 25, 2025 · Past |
Log in to ask 6ix AI your own questions about Biomea Fusion, Inc.